{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:21:09Z","timestamp":1793154069150,"version":"4.5.0"},"reference-count":80,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Serious injection-related infections (SIRIs) cause significant morbidity and mortality. Medication for opioid use disorder (MOUD) improves outcomes but is underused. Understanding MOUD treatment after SIRIs could inform interventions to close this gap.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To examine rehospitalization, death rates, and MOUD receipt for individuals with SIRIs and to assess characteristics associated with MOUD receipt.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used the Massachusetts Public Health Data Warehouse, which included all individuals with a claim in the All-Payer Claims Database and is linked to individual-level data from multiple government agencies, to assess individuals aged 18 to 64 years with opioid use disorder and hospitalization for endocarditis, osteomyelitis, epidural abscess, septic arthritis, or bloodstream infection (ie, SIRI) between July 1, 2014, and December 31, 2019. Data analysis was performed from November 2021 to May 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Demographic and clinical factors potentially associated with posthospitalization MOUD receipt.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was MOUD receipt measured weekly in the 12 months after hospitalization. We used zero-inflated negative binomial regression to examine characteristics associated with any MOUD receipt and rates of treatment in the 12 months after hospitalization. Secondary outcomes were receipt of any buprenorphine formulation, methadone, and extended-release naltrexone examined individually.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 9757 individuals (mean [SD] age, 43.3 [12.1] years; 5701 [58.4%] male) who survived a SIRI hospitalization, 4652 (47.7%) received MOUD, 6518 (66.8%) were rehospitalized, and 1068 (10.9%) died within 12 months. Of those treated with MOUD in the 12 months after hospitalization, the mean (SD) number of MOUD initiations during follow-up was 3.0 (1.8), with 985 of 4652 individuals (21.2%) receiving treatment at least 80% of the time. MOUD treatment after SIRI hospitalization was significantly associated with MOUD in the prior 6 months (buprenorphine: adjusted odds ratio [AOR], 16.63; 95% CI, 14.04-19.71; methadone: AOR, 28.61; 95% CI, 22.80-35.90; or naltrexone: AOR, 2.05; 95% CI, 1.58-2.66). Prior buprenorphine (incident rate ratio [IRR], 1.16; 95% CI, 1.09-1.22) or methadone (IRR, 1.90; 95% CI, 1.79-2.02) use was associated with higher treatment rates after hospitalization, and prior naltrexone use (IRR, 0.85; 95% CI, 0.77-0.95) was associated with lower rates.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study found that in the year after a SIRI hospitalization in Massachusetts, mortality and rehospitalization were common, and only half of patients received MOUD. Treatment with MOUD before a SIRI was associated with posthospitalization MOUD initiation and time receiving MOUD. Efforts are needed to initiate MOUD treatment during SIRI hospitalizations and subsequently retain patients in treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.21740","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T11:43:48Z","timestamp":1721821428000},"page":"e2421740","source":"Crossref","is-referenced-by-count":14,"title":["Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts"],"prefix":"10.1001","volume":"7","author":[{"given":"Simeon D.","family":"Kimmel","sequence":"first","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"},{"name":"Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shapei","family":"Yan","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Grella","sequence":"additional","affiliation":[{"name":"Semel Institute of Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles"},{"name":"Lighthouse Institute, Chestnut Health Systems, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Majeski","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Health, Law and Policy, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bettano","sequence":"additional","affiliation":[{"name":"Office of Population Health, Department of Public Health, Commonwealth of Massachusetts, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Bernson","sequence":"additional","affiliation":[{"name":"Office of Population Health, Department of Public Health, Commonwealth of Massachusetts, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari-Lynn","family":"Drainoni","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"},{"name":"Department of Health, Law and Policy, Boston University School of Public Health, Boston, Massachusetts"},{"name":"Evans Center for Implementation and Improvement Sciences, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Larochelle","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"5","key":"zoi240692r1","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1377\/hlthaff.2015.1424","article-title":"Hospitalizations related to opioid abuse\/dependence and associated serious infections increased sharply, 2002-12.","volume":"35","author":"Ronan","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"zoi240692r2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamacardio.2018.1602","article-title":"Changes in the association of rising infective endocarditis with mortality in people who inject drugs.","volume":"3","author":"Njoroge","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"zoi240692r3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw157","article-title":"Increasing infectious endocarditis admissions among young people who inject drugs.","volume":"3","author":"Wurcel","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"zoi240692r4","doi-asserted-by":"publisher","first-page":"e1649","DOI":"10.1093\/cid\/ciaa1278","article-title":"Evaluating differences in opioid and stimulant use-associated infectious disease hospitalizations in Florida, 2016-2017.","volume":"73","author":"Serota","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi240692r5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.idc.2020.06.004","article-title":"Infective endocarditis in persons who use drugs: epidemiology, current management, and emerging treatments.","volume":"34","author":"Schranz","year":"2020","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"zoi240692r6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac708","article-title":"Methamphetamines and serious injection-related infections: opioid use care continuum and opportunities to end Alabama\u2019s drug crisis.","volume":"10","author":"Levy","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"zoi240692r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.16228","article-title":"Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use-associated infective endocarditis.","volume":"3","author":"Kimmel","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi240692r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225460","article-title":"Mortality, morbidity, and cardiac surgery in Injection Drug Use (IDU)-associated versus non-IDU infective endocarditis: the need to expand substance use disorder treatment and harm reduction services.","volume":"14","author":"Thakarar","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"zoi240692r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5220","article-title":"Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs.","volume":"1","author":"Rodger","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi240692r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060033","article-title":"Infective endocarditis in the U.S., 1998-2009: a nationwide study.","volume":"8","author":"Bor","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"zoi240692r11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz089","article-title":"High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis.","volume":"6","author":"Leahey","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"zoi240692r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.039","article-title":"Touchpoints\u2014opportunities to predict and prevent opioid overdose: a cohort study.","volume":"204","author":"Larochelle","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"zoi240692r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004049","article-title":"Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: a cohort study in New South Wales, Australia.","volume":"19","author":"Brothers","year":"2022","journal-title":"PLoS Med"},{"issue":"15","key":"zoi240692r14","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association.","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"issue":"8","key":"zoi240692r15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003247","article-title":"Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: a nationwide observational study.","volume":"17","author":"Kim","year":"2020","journal-title":"PLoS Med"},{"issue":"4","key":"zoi240692r16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.mcna.2018.03.001","article-title":"Inpatient addiction consult service: expertise for hospitalized patients with complex addiction problems.","volume":"102","author":"Weinstein","year":"2018","journal-title":"Med Clin North Am"},{"issue":"1","key":"zoi240692r17","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1016\/S2468-2667(21)00248-6","article-title":"Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study.","volume":"7","author":"Barocas","year":"2022","journal-title":"Lancet Public Health"},{"issue":"12","key":"zoi240692r18","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s11606-019-05251-9","article-title":"Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis.","volume":"34","author":"Englander","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi240692r19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/add.15236","article-title":"Skin-cleaning among hospitalized people who inject drugs: a randomized controlled trial.","volume":"116","author":"Stein","year":"2021","journal-title":"Addiction"},{"issue":"3","key":"zoi240692r21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/cid\/ciaa062","article-title":"Outcomes associated with medications for opioid use disorder among persons hospitalized for infective endocarditis.","volume":"72","author":"Barocas","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"zoi240692r22","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/cid\/ciy924","article-title":"Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder.","volume":"68","author":"Marks","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi240692r23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac688","article-title":"Integrated infectious disease and substance use disorder care for the treatment of injection drug use-associated infections: a prospective cohort study with historical control.","volume":"10","author":"Serota","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"zoi240692r24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0376-8716(02)00344-7","article-title":"Injection frequency mediates health service use among persons with a history of drug injection.","volume":"70","author":"Stein","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi240692r25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.amjmed.2015.09.024","article-title":"Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis.","volume":"129","author":"Rosenthal","year":"2016","journal-title":"Am J Med"},{"issue":"9","key":"zoi240692r26","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1176\/ajp.130.9.976","article-title":"Engaging heroin addicts in treatment.","volume":"130","author":"Renner","year":"1973","journal-title":"Am J Psychiatry"},{"issue":"5","key":"zoi240692r27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.","volume":"171","author":"Alford","year":"2011","journal-title":"Arch Intern Med"},{"issue":"8","key":"zoi240692r28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11606-010-1311-3","article-title":"A transitional opioid program to engage hospitalized drug users.","volume":"25","author":"Shanahan","year":"2010","journal-title":"J Gen Intern Med"},{"key":"zoi240692r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.05.007","article-title":"Addiction consultation services\u2014linking hospitalized patients to outpatient addiction treatment.","volume":"79","author":"Trowbridge","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"zoi240692r30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s11606-017-4077-z","article-title":"Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity.","volume":"32","author":"Wakeman","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"12","key":"zoi240692r31","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2105\/AJPH.2018.304673","article-title":"Estimated prevalence of opioid use disorder in Massachusetts, 2011-2015: a capture-recapture analysis.","volume":"108","author":"Barocas","year":"2018","journal-title":"Am J Public Health"},{"issue":"3","key":"zoi240692r35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi240692r36","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"1","key":"zoi240692r37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annemergmed.2019.07.030","article-title":"Characteristics and receipt of medication treatment among young adults who experience a nonfatal opioid-related overdose.","volume":"75","author":"Bagley","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"1","key":"zoi240692r38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5993\/AJHB.42.1.14","article-title":"Heroin use and drug injection among youth also misusing prescription drugs.","volume":"42","author":"Rajan","year":"2018","journal-title":"Am J Health Behav"},{"issue":"1","key":"zoi240692r39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"1","key":"zoi240692r40","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz539","article-title":"Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases.","volume":"7","author":"Seval","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi240692r41","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1080\/08897077.2021.2007520","article-title":"Characteristics associated with motivation to stop substance use and improve skin and needle hygiene among hospitalized patients who inject drugs.","volume":"43","author":"Kimmel","year":"2022","journal-title":"Subst Abus"},{"issue":"10","key":"zoi240692r42","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.addbeh.2006.01.003","article-title":"Does this patient really want treatment? factors associated with baseline and evolving readiness for change among hospitalized substance using adults interested in treatment.","volume":"31","author":"Pollini","year":"2006","journal-title":"Addict Behav"},{"key":"zoi240692r43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jsat.2016.02.009","article-title":"Patients\u2019 beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification.","volume":"66","author":"Uebelacker","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi240692r44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review.","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"4","key":"zoi240692r45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial.","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"zoi240692r46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial.","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"2","key":"zoi240692r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi240692r48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23032","article-title":"Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail.","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi240692r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"zoi240692r51","doi-asserted-by":"publisher","first-page":"e650","DOI":"10.1093\/cid\/ciaa365","article-title":"Evaluation of partial oral antibiotic treatment for persons who inject drugs and are hospitalized with invasive infections.","volume":"71","author":"Marks","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi240692r52","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1377\/hlthaff.2021.01242","article-title":"Northeast postacute medical facilities disproportionately reject referrals for patients with opioid use disorder.","volume":"41","author":"Kimmel","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi240692r53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/ADM.0000000000000693","article-title":"Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts.","volume":"15","author":"Kimmel","year":"2021","journal-title":"J Addict Med"},{"key":"zoi240692r54","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103206","article-title":"A qualitative assessment of discharge against medical advice among patients hospitalized for injection-related bacterial infections in West Virginia.","volume":"94","author":"Pollini","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi240692r55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/08897077.2019.1671942","article-title":"Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study.","volume":"41","author":"Simon","year":"2020","journal-title":"Subst Abus"},{"issue":"2","key":"zoi240692r56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/ADM.0000000000000725","article-title":"Medications for opioid use disorder associated with less against medical advice discharge among persons who inject drugs hospitalized with an invasive infection.","volume":"15","author":"Nolan","year":"2021","journal-title":"J Addict Med"},{"issue":"3","key":"zoi240692r57","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa074","article-title":"In-hospital illicit drug use and patient-directed discharge: barriers to care for patients with injection-related infections.","volume":"7","author":"Eaton","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"zoi240692r58","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.amjmed.2011.12.017","article-title":"Increased risk of mortality and readmission among patients discharged against medical advice.","volume":"125","author":"Southern","year":"2012","journal-title":"Am J Med"},{"issue":"1","key":"zoi240692r59","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/08897077.2022.2074601","article-title":"Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: a retrospective cohort analysis.","volume":"43","author":"Priest","year":"2022","journal-title":"Substance Abuse"},{"issue":"12","key":"zoi240692r60","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.2105\/AJPH.2020.305888","article-title":"Racial and ethnic disparities in maternal and infant outcomes among opioid-exposed mother-infant dyads in Massachusetts (2017-2019).","volume":"110","author":"Peeler","year":"2020","journal-title":"Am J Public Health"},{"issue":"9","key":"zoi240692r61","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment.","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi240692r62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mcna.2021.08.008","article-title":"Disparities in addiction treatment: learning from the past to forge an equitable future.","volume":"106","author":"Jackson","year":"2022","journal-title":"Med Clin North Am"},{"key":"zoi240692r63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108551","article-title":"Experiences of racial discrimination in the medical setting and associations with medical mistrust and expectations of care among black patients seeking addiction treatment.","volume":"133","author":"Hall","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"zoi240692r64","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2105\/AJPH.2021.306431","article-title":"Disparities in opioid overdose death trends by race\/ethnicity, 2018-2019, from the HEALing Communities Study.","volume":"111","author":"Larochelle","year":"2021","journal-title":"Am J Public Health"},{"issue":"8","key":"zoi240692r65","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1001\/jamapsychiatry.2021.0967","article-title":"Racial\/ethnic, social, and geographic trends in overdose-associated cardiac arrests observed by US emergency medical services during the COVID-19 pandemic.","volume":"78","author":"Friedman","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"zoi240692r66","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/PHH.0000000000001168","article-title":"Structural racism and the opioid overdose epidemic: the need for antiracist public health practice.","volume":"26","author":"Kunins","year":"2020","journal-title":"J Public Health Manag Pract"},{"issue":"11","key":"zoi240692r67","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3928\/00485713-20201008-01","article-title":"Systemic racism and substance use disorders.","volume":"50","author":"Farahmand","year":"2020","journal-title":"Psychiatr Ann"},{"key":"zoi240692r68","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-022-00985-w","article-title":"Impact of alternative ways to operationalize buprenorphine treatment duration on understanding continuity of care for opioid use disorder.","author":"Dong","journal-title":"Int J Ment Health Addict"},{"key":"zoi240692r69","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108717","article-title":"Opioid use disorder treatment for people experiencing homelessness: a scoping review.","volume":"224","author":"McLaughlin","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi240692r70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108752","article-title":"\u201cSick and tired of being sick and tired\u201d: exploring initiation of medications for opioid use disorder among people experiencing homelessness.","volume":"138","author":"Swartz","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi240692r71","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0477","article-title":"Office-based addiction treatment retention and mortality among people experiencing homelessness.","volume":"4","author":"Fine","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi240692r72","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42676","article-title":"Drug overdose mortality among people experiencing homelessness, 2003 to 2018.","volume":"5","author":"Fine","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi240692r73","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/dar.12930","article-title":"Uptake into a bedside needle and syringe program for acute care inpatients who inject drugs.","volume":"38","author":"Brooks","year":"2019","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"zoi240692r74","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1080\/07853890.2021.1993326","article-title":"Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team.","volume":"53","author":"Serota","year":"2021","journal-title":"Ann Med"},{"issue":"1","key":"zoi240692r75","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12954-017-0163-0","article-title":"Harm reduction in hospitals.","volume":"14","author":"Sharma","year":"2017","journal-title":"Harm Reduct J"},{"key":"zoi240692r76","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108646","article-title":"A randomized controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among people who inject drugs.","volume":"221","author":"Phillips","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi240692r77","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/ADM.0000000000000934","article-title":"Low-threshold buprenorphine treatment in a syringe services program: program description and outcomes.","volume":"16","author":"Jakubowski","year":"2022","journal-title":"J Addict Med"},{"issue":"5","key":"zoi240692r79","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s11904-023-00667-9","article-title":"Integrated care models: HIV and substance use.","volume":"20","author":"Hill","year":"2023","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"zoi240692r80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13722-024-00455-9","article-title":"Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder.","volume":"19","author":"Bart","year":"2024","journal-title":"Addict Sci Clin Pract"},{"key":"zoi240692r20","doi-asserted-by":"crossref","DOI":"10.17226\/25310","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"Leshner","year":"2019"},{"key":"zoi240692r32","unstructured":"Commonwealth of Massachusetts. Chapter 55: An Act Requiring Certain Reports for Opiate Overdoses. Published August 5, 2015. Accessed September 16, 2020. https:\/\/malegislature.gov\/laws\/sessionlaws\/acts\/2015\/chapter55"},{"key":"zoi240692r33","unstructured":"Massachusetts Department of Public Health. Public Health Data Warehouse (PHD): Overview. Accessed February 1, 2023. https:\/\/www.mass.gov\/info-details\/public-health-data-warehouse-phd-overview"},{"key":"zoi240692r34","unstructured":"Commonwealth of Massachusetts. Outside Section 48: Public Health Data 1. FY2018 Budget Summary. Published 2017. Accessed October 3, 2023. https:\/\/budget.digital.mass.gov\/bb\/gaa\/fy2018\/os_18\/h48.htm"},{"key":"zoi240692r50","unstructured":"Bart? G, Korthuis? PT. Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (Protocol 0098). National Institute on Drug Abuse, Clinical Trials Network. Accessed June 6, 2024. https:\/\/www.drugabuse.gov\/about-nida\/organization\/cctn\/ctn\/research-studies\/exemplar-hospital-initiation-trial-to-enhance-treatment-engagement-exhit-entre-nih-heal-initiative"},{"key":"zoi240692r78","unstructured":"National Institute on Drug Abuse. Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE). Accessed June 6, 2024. https:\/\/nida.nih.gov\/about-nida\/organization\/cctn\/ctn\/research-studies\/exemplar-hospital-initiation-trial-to-enhance-treatment-engagement-exhit-entre-nih-heal-initiative"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2821462\/kimmel_2024_oi_240692_1730229351.19921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T11:00:51Z","timestamp":1730458851000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2821462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21740","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}